(S,R,S)-AHPC-C1-Br

Background Introduction

(S,R,S)-AHPC-C1-Br is a specialized E3 ligase ligand-linker conjugate widely utilized in the development of PROTAC (Proteolysis Targeting Chimera) molecules. This compound is designed to bind the von Hippel-Lindau (VHL) E3 ligase, which plays a pivotal role in targeted protein degradation technologies for both research and drug discovery.

Mechanism

(S,R,S)-AHPC-C1-Br functions as a modular component in PROTAC design by harnessing its high affinity for the VHL E3 ligase. The AHPC moiety acts as a VHL ligand, while the C1-branched linker provides an adaptable attachment point for heterobifunctional conjugation. When incorporated into a PROTAC, this conjugate bridges the E3 ligase and a target protein via a custom-designed warhead. This proximity induces ubiquitination of the target protein, ultimately leading to its recognition and degradation by the proteasome.

Applications

(S,R,S)-AHPC-C1-Br is instrumental in the rational design and synthesis of VHL-based PROTACs for the study and therapeutic targeting of disease-relevant proteins. Its applications include the creation of protein degraders for cancer research, validation of disease targets, and the development of next-generation targeted therapies. This conjugate is also valuable in constructing custom PROTAC libraries and advancing small molecule-induced protein degradation strategies in both academic and pharmaceutical industry settings.

The (S,R,S)-AHPC-C1-Br E3 Ligase Ligand-Linker Conjugate is an innovative component in the design of PROTACs, facilitating targeted protein degradation by bridging E3 ligases and target proteins. This description provides insights into the linker, ligand, and reactive site, assisting researchers in selecting appropriate target protein ligands for experimental applications.

Linker: The linker in (S,R,S)-AHPC-C1-Br is of moderate length, offering a balance between flexibility and rigidity to optimize interaction dynamics. Its non-cleavable nature ensures stability within the cellular environment, enhancing the efficacy of the PROTAC complex.

Ligand: The ligand component is derived from AHPC, a potent E3 ligase recruiter with chiral specificity. Its stereochemistry is crucial for selective binding to the intended E3 ligase, promoting efficient ubiquitination and degradation of the target protein.

Reactive Site: The bromine atom in (S,R,S)-AHPC-C1-Br serves as the reactive site, ready to couple with the target protein ligand. Recommended reaction types include nucleophilic substitution, which facilitates covalent bond formation with the warhead, enhancing the PROTAC's stability and activity.

Recommended Target Protein Ligand: The ideal warhead for this conjugate is a nucleophilic moiety capable of efficient displacement of the bromine atom. Such warheads are advantageous due to their ability to form stable covalent bonds, ensuring robust interaction with the target protein. This facilitates precise degradation of proteins implicated in various cellular pathways, offering valuable insights for research in protein function and regulation.